Related Experiment Video

Updated: Jul 2, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Targeting the hERG1 and β1 integrin complex for cancer treatment

Annarosa Arcangeli1,2,3, Jessica Iorio1, Claudia Duranti1,3

  • 1Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Firenze, Italy.

Expert Opinion on Therapeutic Targets
|February 19, 2024
PubMed
Abstract

Insights

Novel bispecific antibodies targeting the hERG1/β1 integrin complex offer a promising strategy for antineoplastic therapy. This approach overcomes cardiac toxicity associated with traditional hERG1 blockers, showing potential in preclinical cancer models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Novel therapeutic strategies are crucial for metastatic carcinomas, including breast, colorectal, pancreatic, and renal cancers.
  • Ion channels, particularly the hERG1 potassium channel, are emerging as significant cancer biomarkers and therapeutic targets.
  • Aberrant expression of hERG1 is observed in aggressive human cancers.

Purpose of the Study:

  • To investigate the hERG1 potassium channel as a novel target for antineoplastic therapy.
  • To develop a targeted therapeutic strategy that overcomes the limitations of traditional hERG1 blockade.
  • To evaluate the antineoplastic effects of a novel bispecific antibody targeting the hERG1/β1 integrin complex.

Main Methods:

  • Identification of the unique hERG1 conformation in cancer cells, specifically its complex with the β1 integrin subunit.
  • Development of a single chain bispecific antibody (scDb-hERG1-β1) designed to target the hERG1/β1 integrin complex.
  • Preclinical evaluation of the antineoplastic efficacy of the scDb-hERG1-β1 antibody.

Main Results:

  • The hERG1/β1 integrin complex is uniquely present in cancer cells and not in cardiac tissue.
  • The developed bispecific antibody, scDb-hERG1-β1, specifically targets the hERG1/β1 integrin complex.
  • Preclinical experiments demonstrated antineoplastic effects mediated by the scDb-hERG1-β1 antibody.

Conclusions:

  • Targeting the hERG1/β1 integrin complex represents a viable strategy to specifically target hERG1 in cancer.
  • The bispecific antibody scDb-hERG1-β1 offers a potential solution to circumvent cardiac toxicity associated with general hERG1 blockers.
  • This targeted approach holds promise for the development of new antineoplastic therapies for various carcinomas.
Keywords:
Bispecific antibodiesKCNH2Kv 11.1cancer signalingcancer treatmention channelsmetastasistherapeutic antibodies

More Related Videos

A 3D Spheroid Model as a More Physiological System for Cancer-Associated Fibroblasts Differentiation and Invasion In Vitro Studies06:27

A 3D Spheroid Model as a More Physiological System for Cancer-Associated Fibroblasts Differentiation and Invasion In Vitro Studies

Published on: August 8, 2019

8.9K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.4K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.7K
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K